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Background: The gradual ageing of the Galician population is a
fact that has been observed in recent years. In 1930, 16.1%
of the population was over 65 years old and in 2010 these
ﬁgures had increased to nearly 23%. Every year the number
of patients diagnosed with inﬂammatory bowel disease (IBD) at
more advanced ages has been increasing. The aim of the study
was to assess the clinical characteristics of IBD patients that
were diagnosed at advanced ages.
Methods: A Retrospective observational study was performed
by IBD specialists from 7 Hospitals belonging to EIGA (The
Galician Association for Research into Inﬂammatory Bowel
Disease). The inclusion criteria were all IBD patients that
had been diagnosed over 60 years of age. Epidemiological
characteristics like classiﬁcation of disease in accordance with
the Montreal classiﬁcation, gender, family history of IBD,
use of steroids, immunosuppressive or biological drugs and
need for surgery were performed. The results are shown in
percentages.
Results: 252 IBD patients were included: 162 (64.2%) with
ulcerative colitis (UC) and 90 (35.8%) with Crohn’s disease (CD).
Regarding UC patients, 64% were male, and 96% had no family
history of IBD. 29% of patients were older than 70 years of age
at diagnosis. In accordance with the Montreal classiﬁcation,
35.8% were E1, 46% E2 and 17.8% E3. In patients diagnosed
between 60 and 70 years old, E2 (46.2%) was more frequent,
but in patients over 70 years old, the most frequent extensions
were E2 (46.35%) and E1 (43.6%). 30% needed steroids,
developing 9.8% steroid-dependency; immunosuppressive drugs
were needed for 11.7% and biological drugs for 3.7%. Only 2.4%
of the patients required colectomy. Among CD patients, 56%
were male, and 98% had no family history of IBD. 51% of patients
were older than 70 years of age at diagnosis. In accordance
with the Montreal classiﬁcation, the most common location
was L1 (48.8%). 57.7% of the patients presented B1 phenotype;
24.4% B2 and 16.6% B3. Perianal disease was present in 11.1% of
CD patients. 52.2% needed steroids, developing 18.8% steroid-
dependency; immunosuppressive drugs were needed for 26.6%
(in all with perianal disease) and biological drugs for 13.3%. CD
surgery was required for 18.8%.
Conclusions: In elderly IBD patients, UC seems to be more
common than CD. Most cases of UC are limited to left side
colitis and the need for aggressive therapies is very limited.
CD patients who develop perianal disease should be given
immunosuppressive or biological drugs.
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Background: Low bone mineral density (BMD) is common in
patients with inﬂammatory bowel disease and is a leading cause
of morbidity in such patients. Data about bone disease in male
with ulcerative colitis (UC) is scarce. Our aim was to assess the
prevalence of low BMD among male UC patients on a nationwide
level.
Methods: Nationwide data was obtained from the Veterans
Affairs (VA) healthcare system. Male veterans seen by the
VA between 2001 and 2011 were identiﬁed using ICD-9 and
were included in our analysis. Automated data extraction
captured information about the veterans’ demographics,
presence of bone disease and the other risk factors for low BMD
[corticosteroid (CS) use, hyperparathyroidism, hypogonadism,
malnutrition, vitamin D deﬁciency and smoking]. The rate
of bone disease by cumulative CS decile was calculated.
Multivariate logistic regression analysis was used to identify the
independent effect of each factor on bone disease.
Results: We included 34,665 male UC patients (mean age
66, Caucasians 75%). Prevalence of osteoporosis among the
included population was 6.5%, while for osteopenia it was
4.3%. Those who used CS (30% of the included population
with mean duration of nine months) had higher prevalence
of bone diseases (10.2% and 7%) compared to those who did
not use CS (4.8% and 3.2%) for osteoporosis and osteopenia
respectively, p < 0.001. By using multivariate analysis, we found
that cumulative oral CS deciles was the most signiﬁcant
independent predictor of bone disease and showed a signiﬁcant
trend (dose-response) pattern even in those with lowest decile
of cumulative CS exposure.
Table 1. Multivariate logistic regression analysis, outcome is
having bone disease (osteoporosis or osteopenia)
Total N
of
patients
% of patients
with bone
disease
Odds
ratio
p 95% CI
Age
1st quartiles (20 59) 8666 6.5%
4th quartile (77 105) 8671 14.8% 3.31 <0.001 (2.9 3.7)
Hyperparathyroidism 414 34.3% 2.76 <0.001 (2.2 3.5)
Hypogonadism 1386 23.1% 2.36 <0.001 (2 2.7)
Smoking 2708 14.2% 1.23 <0.001 (1.09 1.4)
Vitamin D deﬁciency 2053 26.8% 2.95 <0.001 (2.6 3.3)
Prednisone cumulative dose (deciles)
No exposure 24091 8.0%
1st (<180 mg) 1061 11.3% 1.51 <0.001 (1.2 1.8)
10th (>11136 mg) 1057 41.0% 8.90 <0.001 (7.7 10)
CI, conﬁdence interval.
Conclusions: In this large nationwide male UC cohort, 41%
of those in the highest CS use decile had osteoporosis or
osteopenia. CS use is the most important independent risk
factor for low bone density among UC male patients. Efforts
should be taken to reduce CS utilization among these patients
by using other immunosuppressant agents.
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Background: A nationwide registry may serve as a mirror
reﬂecting the quality of health care. It is a method for detecting
failure in diagnostic workup or in management practice.
We evaluated whether diagnostic workup of paediatric
inﬂammatory bowel disease (IBD) patients fulﬁls Porto Criteria.
Furthermore, we analyzed whether the diagnostic practice has
changed since the Hungarian Paediatric IBD Registry exists.
In addition, there has been no large paediatric IBD cohort
analyzed according to Paris classiﬁcation.
Methods: Newly diagnosed paediatric patients with IBD
(0 18 years) are registered in this prospective registry.
All the twentyseven paediatric institutes with paediatric
gastroenterology serve data ensuring a nationwide approach.
The questionnaire includes epidemiological data, disease
extension, disease activity (PCDAI, PUCAI) and initial therapy.
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Results: Between 2007 and 2011, 712 new IBD cases were
identiﬁed (449 Crohn’s disease (CD), 217 ulcerative colitis (UC)
and 46 IBD-unclassiﬁed). Upper endoscopy was performed in
52.6% of the patients in 2007, and this rate has increased to
78.2% by 2011. Proportion of ileoscopy has changed from 53% to
69%. Imaging of the small bowel did not change during the years
(range: 31.2 42%), but the modality of imaging has altered. MRI
was performed in 7.5% of patients in 2007 and in 24.8% in 2011.
Localization (Paris classiﬁcation) could be evaluated in 512
patients. 84/173 UC patients had E4 classiﬁcation, 32 children
had E3 localization and 10 cases presented with proctitis. S1
severity was found in 15 patients (11.5%) at diagnosis.
In CD 219 (64%) children had upper gastrointestinal involve-
ment, 72.6% patients had L4a, 12.3% had L4b, and 15.1% had
L4ab classiﬁcation. Six patients (1.4%) belonged to B2B3, 10
children (2.3%) had B3 and 46 (10.4%) CD patients had B2
phenotype. Localization differed in age groups: involvement
of the terminal ileum was signiﬁcantly lower in A1a age group
than in A1b (U=6216, p < 0.001) or A2 groups (U=768, p = 0.022).
Perianal disease was signiﬁcantly higher in patients with L4b
than in L4a (25.9% vs. 9.4% p = 0.023). PCDAI was signiﬁcantly
higher in patients with L3 than in patients with L1 or L2
disease extension (35.9 vs. 28.2 (p = 0.001) and 35.9 vs. 27.2
p < 0.001).
Conclusions: The quality of diagnostic workup in paediatric
patients with IBD improved in the last 5 years. Paris
classiﬁcation of the IBD patients seems to be a more precise
classiﬁcation, providing distinct subgroups for further analysis.
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Background: Inﬂammatory bowel diseases (IBD) are associated
with a variety of extraintestinal manifestations, involving the
respiratory system. The relation between IBD and asthma is
not clear and whether it is an extraintestinal manifestation it
is unknown. The aim of the study was to assess the prevalence
of asthma in IBD patients.
Methods: A prospective study was designed. The case-
studies all consisted of consecutive patients with IBD (Crohn’s
disease [CD] and ulcerative colitis [UC]) over 18 years of
age who attended the monographic IBD unit for 6 months
and who agreed to participate in the study. All were sent
to the Respiratory department where the same protocol was
performed. All patients completed the European Community
Respiratory Health Survey (ECRHS) questionnaire. A spirometry
with bronchodilator, a fractional exhaled nitric oxide (FeNO)
test and a skin allergy test using the skin prick test method
(SPT) were also performed. Probable asthma was considered
as afﬁrmative answer to one of the next questions of the
ECRHS questionnaire: 1) Have you been woken by an attack
of shortness of breath at any time in the last 12 months?;
2) Have you been woken by an attack of coughing at any
time in the last 12 months?; 3) Have you woken up with a
feeling of tightness in your chest at any time in the last
12 months?; 4) Have you had an attack of asthma in the last
12 months?; 5) Are you currently taking any medicines including
inhalers, aerosols or tablets for asthma?. Conﬁrmed asthma was
diagnosed in cases with Probable asthma if values in the FeNO
test were over 30 ppb or a change in the FEV1 was over 12%
and 200ml. Results are shown in percentages.
Results: 132 patients were consecutively included, 53 (40.1%)
CD; 79 (59.9%) UC, having a mean age of 45 years, ranging from
18 to 77, 65 (49.2%) being female. In UC more were men (59%)
and in CD more were women (60%) (p = 0.03). Regarding asthma
determination, 31 patients (23.5%) presented asthma symptoms
in the ECRHS questionnaire. The prick test was positive in 31.3%
of patients, the FeNO test was over 30 ppm in 24.1% of patients
and a positive bronchodilator test was observed in 30.5% of
patients. Overall we observed a probable asthma in 23.5% of
all IBD patients and conﬁrmed asthma in 16.9% of our sample.
These ﬁgures are clearly higher than in an average population
where asthma is present in around 5% of people.
Conclusions: Asthma prevalence seems to be high among our
IBD patients, being superior to that of the average population.
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Background: Microscopic colitis (MC) predominantly affects to
middle and old age population, where consumption of drugs is
more common. Some drugs have been suggested as causative
or triggering agent of MC. Various autoimmune conditions are
often seen in patients with MC. The aim of our study is to
assess the epidemiological characteristics and the association
between MC, drugs and autoimmune disease in our region.
Methods: A retrospective and descriptive study of all patients
diagnosed with (MC) within 01.01.2009 31.12.2011 where con-
ducted. We included patients diagnosed with collagenous colitis
(CC), lymphocytic colitis (LC) and incomplete microscopic
colitis (MCi).
Results: We retrospectively analyzed 44 new cases diagnosed
in the last three years, in four tertiary hospitals catering
to a population of 838,000 people. The incidence rate of
microscopic colitis that we observed, inhabitants aged 15 years
or over, is 1.7 cases per 100,000 inhabitants per year. The
majority of cases happened in females (72%). The median age
of diagnosis of the disease is 62 years-old. 38% of patients were
older than 70 years, and no one were younger than 30 years at
the time of diagnosis. Histologic examination shows the same
incidence for both types (LC and CC) 40%. 74% of patients
were taking any of these drugs: Proton Pump Inhibitors therapy
(PPI), selective serotonin reuptake inibitors (SSRI), statins or
non steroidal antiinﬂammtory drugs (NSAIDs). The association
with autoimmune diseases is 20%, being reumatoid arthritis the
most commonly associated disease (33%), in this group, the
most common histology is the LC (70%).
Conclusions: There is a high percentage of patients diagnosed
with MC taking PPI, statins drugs, NSAIDs or SSRIs. We observe
that reumatoid arthritis is the most common autoimmune
disease associated with the diagnosis of microscopic colitis in
our patients.
